Key clinical point: Pediatric patients with polyarticular-course juvenile idiopathic arthritis who achieved JIA ACR30 response criteria after 18 weeks of tofacitinib had a significantly lower rate of disease flare after an additional 26 weeks with continued tofacitinib treatment than with placebo.
Major finding: Patients taking tofacitinib had a lower rate of disease flare by 44 weeks (29.2% vs. 52.9% with placebo; P = .0031), and a 54% lower risk of disease flare (hazard ratio, 0.459; 95% confidence interval, 0.268-0.785; P = .0037).
Study details: A phase 3, randomized, double-blind, placebo-controlled withdrawal study of tofacitinib in 225 patients between 2 years and less than 18 years old with polyarticular-course juvenile idiopathic arthritis who first achieved a JIA ACR30 response during an 18-week run-in phase and then received tofacitinib or placebo for an additional 26 weeks.
Disclosures: The researchers reported ties with Pfizer, which funded the study, and more than two dozen other pharmaceutical companies.
Brunner HI et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract L22.